Profire Energy (PFIE) Reports Q2 Loss of $0.42

Profire Energy (NASDAQ: PFIE) reported Q2 EPS of ($0.42), versus ($0.70) reported last year.

“We are very pleased with our progress in the second quarter,” said Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals. “In May, the FDA accepted our NDA resubmission for EYSUVIS, bringing us closer to potentially delivering the first prescription medicine for the short-term treatment of dry eye disease, including dry eye flares, which affects approximately 33 million people in the United States. We have now turned our attention toward a potential U.S. launch before year-end. Given our established relationships with eye care professionals across the United States and our experience with INVELTYS, we believe we are well-positioned for a successful launch of EYSUVIS, if approved.”

For earnings history and earnings-related data on Profire Energy (PFIE) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery